ROS1 and non-small cell lung carcinoma: A review of over 30,000 tumors excluding those with NSCLC or lymphoma from two of these commercial vendors identified ALK rearrangements in 1/1,000 specimens and ROS1 rearrangements in 4/10,000 specimens.